|
作用机制HMG-CoA reductase抑制剂 [+1] |
|
|
|
非在研适应症- |
最高研发阶段批准上市 |
|
首次获批日期2019-08-30 |
靶点- |
作用机制- |
|
|
|
非在研适应症- |
最高研发阶段临床1期 |
首次获批国家/地区- |
首次获批日期- |
靶点- |
作用机制- |
|
|
|
非在研适应症- |
最高研发阶段临床1期 |
首次获批国家/地区- |
首次获批日期- |
A randomized, open-label, single dose, crossover clinical study to investigate the effect of food on the pharmacokinetics of EL-1804 in healthy adult subjects
A randomized, open-label, multiple doses, crossover clinical study to compare the pharmacokinetic characteristics and the safety between administration of EL-1804 and co-administration of EL-1804R-1 and EL-1804R-2 in healthy adult subjects
The phase 1 study to evaluate the pharmacokinetic drug-drug interaction and safety between EL-1804R-1 and EL-1804R-2 in healthy male volunteers
100 项与 Elyson Pharm Co., Ltd. 相关的临床结果
0 项与 Elyson Pharm Co., Ltd. 相关的专利(医药)
100 项与 Elyson Pharm Co., Ltd. 相关的药物交易
100 项与 Elyson Pharm Co., Ltd. 相关的转化医学